Your browser doesn't support javascript.
loading
Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells.
Shah, Mittal; Maroof, Asher; Gikas, Panos; Mittal, Gayatri; Keen, Richard; Baeten, Dominique; Shaw, Stevan; Roberts, Scott J.
Affiliation
  • Shah M; UCB Pharma, Slough, UK.
  • Maroof A; Division of Surgery and Interventional Science, University College London, London, UK.
  • Gikas P; UCB Pharma, Slough, UK.
  • Mittal G; Royal National Orthopaedic Hospital Stanmore, Stanmore, UK.
  • Keen R; Royal National Orthopaedic Hospital Stanmore, Stanmore, UK.
  • Baeten D; Royal National Orthopaedic Hospital Stanmore, Stanmore, UK.
  • Shaw S; UCB Pharma, Slough, UK.
  • Roberts SJ; UCB Pharma, Slough, UK.
RMD Open ; 6(2)2020 07.
Article in En | MEDLINE | ID: mdl-32723833
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Osteogenesis / Periosteum / Cell Differentiation / Interleukin-17 / Antibodies, Monoclonal, Humanized Limits: Humans Language: En Journal: RMD Open Year: 2020 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Osteogenesis / Periosteum / Cell Differentiation / Interleukin-17 / Antibodies, Monoclonal, Humanized Limits: Humans Language: En Journal: RMD Open Year: 2020 Document type: Article Affiliation country: Country of publication: